Clinical Assessment of BIOGUARD(R) Dressings With NIMBUS Technology Shown to Prevent Bacterial Growth, Reduce Wound Odor and Frequency of Dressing Changes

/ Source: GlobeNewswire

GAINESVILLE, Fla., April 7, 2011 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCQB:QMDT) announced today that clinicians from the Burn Center at Shands at the University of Florida have reported very positive initial observations from their use of BIOGUARD® wound dressings with Quick-Med's novel NIMBUS® antimicrobial technology in an ongoing clinical assessment. These results will be presented in "Gauze Bandages with a Bound Antimicrobial Polymer Suppress Bacterial Growth in Patients with Heavily Exudating Wounds" at the 2011 Symposium on Advances in Wound Care / Wound Healing Society meeting. The Symposium is the premier meeting of physicians, researchers and other wound care specialists and is being held in Dallas, Texas, on April 14-17, 2011.

The assessment is being conducted at the UF Shands burn unit at the University of Florida by a team led by Robert Nappo, MSN, ARNP, Nurse Manager, with the objective of overcoming chronic shortcomings of common dressings. Nappo reports that BIOGUARD dressings have reduced the need for frequent dressing changes and that both caregivers and patients are pleased with the results. "We rarely consider new product claims, but BIOGUARD works so well on heavily exudating wounds that we are replacing all standard rolled gauze products with BIOGUARD," stated Nappo.

The results of the Shands study vividly demonstrate that NIMBUS technology not only prevents rapid bacterial growth in gauze dressings saturated with heavy wound exudates but also eliminates the associated strong objectionable odor that is characteristic of bacterial contamination in such dressings. The assessment involved direct comparison of standard gauze and BIOGUARD dressings on patents with very large, exudating wounds covering more than 70 percent of total body surface area. In each case, the standard gauze bandages developed a metallic green color and strong odor characteristic of Pseudomonas aeruginosa within 24 hours of applying the bandage. In marked contrast, BIOGUARD gauze bandages applied to wounds adjacent to the standard gauze remain white with no discoloration or other visible evidence of bacterial fouling.

"These excellent clinical results from Shands demonstrate the superior ability of NIMBUS technology to significantly reduce bacterial bioburden in dressings on problematic, highly exudating wounds," said Roy Carr, Business Development Director for Quick-Med. "This new clinical evidence reinforces the important contribution that our novel, non-leaching, non toxic, and low cost NIMBUS technology is making to improving wound care."

Lisa Youngblood, RN, of the Shands UF Burn Center, will present the study results at the 2011 Symposium. BIOGUARD dressings are manufactured by Derma Sciences, Inc. and distributed by Medline Industries to Shands Hospitals in Gainesville and Jacksonville.


Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received De Novo FDA clearance in 2009 and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by ten U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, and catheters.

About the Symposium on Advances Wound Care/Wound Healing Society

Now in its 24th year, the Symposium is the premier educational wound care program within this clinical field and is one of the largest annual gatherings of wound care clinicians in the United States.

About Shands at the University of Florida

Shands at the University of Florida is a private, not-for-profit hospital specializing in tertiary care for critically ill patients. Shands at UF continually receives recognition as one of the best hospitals in the nation by U.S. News and World Report because of its dedication to patient care, education and research. It is the primary teaching hospital for the UF College of Medicine. More than 500 physicians representing 110 medical specialties work with a team of healthcare professionals to provide quality care for patients. The faculty from the UF College of Medicine includes nationally and internationally recognized physicians whose expertise is supported by intensive research activities.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing advanced antimicrobial technologies for infection prevention and control for the consumer and healthcare markets. The Company is developing NIMBUS applications in several other advanced wound dressing formats including adhesives, foams, hydrogels, films, and hydrocolloids. Its NimbuDerm™ technology is being developed as a persistent hand sanitizer and its Stay Fresh® technology, the Company's latest innovation, provides highly durable antimicrobial protection for apparel and other textile applications. For more information, see: .

The Quick-Med Technologies, Inc. logo is available at

© 2011 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® and Stay Fresh® are registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc. BIOGUARD® is a registered trademark of Derma Sciences, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at .

CONTACT: Quick-Med Technologies, Inc. Roy Carr, Director Business Development (888) 835-2211, ext 106 Stonegate Securities, Inc. Casey Stegman (investor/media contact) (214) 987-4121